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Depression and anxiety in multisomatoform disorder: 
Prevalence and clinical predictors in primary care
Jacqueline E Muller, Ignatius Wentzel, Daniel G Nel, Dan J Stein
Somatisation in primary care patients is a common and 
disabling condition found in the populations of all countries 
and cultures studied.1 Physical symptoms precipitate more 
than half of all primary care visits, and at least a third of such 
symptoms remain medically unexplained.2,3 Patients with 
somatisation are frequent users of medical care; and excessive 
clinic visits, diagnostic testing, referrals, prescriptions and 
procedures all contribute to increased health care costs.4,5 
Somatisation results in considerable disability, impairment in 
various life domains, and health anxiety.5 Furthermore, the 
somatising patient is often dissatisfied with health care services 
and is rated by clinicians as being among their most difficult 
and unsatisfying encounters.5,6
Psychiatric co-morbidity is common in patients with 
somatisation. Multiple medically unexplained symptoms 
increase the likelihood of a co-existing psychiatric diagnosis, 
with as many as half of patients having an anxiety disorder, 
and two-thirds a depressive disorder.3,5,7-9 Moreover, there 
is some evidence that functional impairment is higher in 
somatoform disorder with a co-morbid depressive or anxiety 
disorder.7
Multisomatoform disorder (MSD) is a diagnosis from 
the Diagnostic and Statistical Manual of Mental Disorders, 4th 
edition, Primary Care Version (DSM-IV PC), encompassing 
the moderately severe form of undifferentiated somatoform 
disorder, with a prevalence of 8 - 10% in primary care.5,10 
MSD is characterised by 3 or more currently troublesome 
medically unexplained symptoms together with a 2-year 
history of somatisation. If part of the criteria for a current 
mental disorder, physical symptoms do not count toward 
the diagnosis of MSD (e.g. palpitations exclusively during a 
panic attack). Those with MSD have impaired functioning 
comparable to somatisation disorder, are at increased risk for 
co-morbid depressive and anxiety disorders, are more prone to 
be unsatisfied with their health care, and are more likely to be 
viewed as difficult patients.3,5
The aim of this study was to evaluate the prevalence of 
depressive and anxiety disorders in a South African sample 
with MSD, and to compare various demographic and clinical 
outcomes between those with and without co-morbidity, based 
on the hypothesis that MSD with co-morbid depressive and 
anxiety disorders would be associated with greater functional 
impairment than MSD without co-morbidity.
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Objective. Multisomatoform disorder (MSD) is characterised 
by ≥3 medically inexplicable, troublesome physical 
symptoms, together with a ≥2-year history of somatisation. 
The aim of this study was to evaluate the prevalence of 
depressive and anxiety disorders in a South African sample 
MSD, and to compare demographic and clinical outcomes in 
those patients with and without co-morbidity.
Methods. Fifty-one adult outpatients with MSD were 
recruited from primary care clinics in the Cape Town 
metropole. Participants were assessed for the presence of 
co-morbid depressive and anxiety disorders using the Mini 
Neuropsychiatric Interview-Plus (MINI-Plus). Outcomes 
included somatic symptom severity, disability, reported 
sick days and health care visits, pain experience, patient 
satisfaction with health services, and clinician-experienced 
difficulty.
Results. A current co-morbid depressive disorder was present 
in 29.4% (N=15) of patients, and a current co-morbid anxiety 
disorder in 52.9% (N=27). MSD patients with a co-morbid 
depressive disorder (current or lifetime) had significantly 
higher physical symptom counts, greater functional 
impairment, higher unemployment rates, more clinician-
reported difficulties, and more dissatisfaction with health care 
services than those without the disorder. A larger number 
of co-morbid disorders was associated with greater overall 
disability.
Conclusion. High rates of co-morbid depressive and anxiety 
disorders were present in a South African sample of primary 
care patients with MSD. Not all patients had co-morbidity, 
which is consistent with the view that MSD should be viewed 
as an independent disorder. However, co-morbid depressive 
disorders were associated with increased symptom severity 
and functional impairment, consistent with previous reports 
from developing countries, emphasising the importance of co-
morbidity in MSD.
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Methods
Subjects
Fifty-one adult outpatients meeting diagnostic criteria 
for MSD were recruited from primary care clinics in the 
Cape Town area. Participants were recruited for a selective 
serotonin reuptake inhibitor (SSRI) treatment study,11 and 
data on co-morbid disorders were collected in this group. 
Exclusion criteria included current or past bipolar mood 
disorder, psychotic disorder or substance abuse/dependence, 
serious unstable medical illness, pregnancy or breastfeeding, 
significant risk of suicide, concurrent cognitive behavioural 
therapy, or use of psychotropic medication.
The study was designed and conducted in accordance with 
the Declaration of Helsinki, and the Stellenbosch University 
institutional review board approved the protocol. All 
participants provided written, informed, voluntary consent.
Outcomes
Participants were assessed for the presence of co-morbid 
depressive and anxiety disorders using a structured 
diagnostic interview based on DSM-IV criteria and the Mini 
Neuropsychiatric Interview-Plus (MINI-Plus),  
Version 5.12 Those with somatic symptoms only in the context 
of a psychiatric disorder other than MSD (e.g. dizziness 
occurring only during a panic attack) were excluded. 
Demographic data were collected, together with reported 
sick days and health care visits in the 3 months preceding the 
assessment.
The Patient Health Questionnaire (PHQ-15) was used to 
measure severity of functional somatic symptoms.2 The PHQ-
15 comprises 15 commonly encountered somatic symptoms, 
each scored from 0 (‘not bothered at all’) to 2 (‘bothered a lot’).
Additional measures included the Sheehan Disability Scale 
(SDS),13 a Visual Analogue Pain Rating Scale (VAS-P),14 the 
10-item Difficult Doctor Patient Relationship Questionnaire 
(DDPRQ-10),6 and a consumer satisfaction subscale from the 
Consumer Assessment of Health Plan Study (CAHPS).15
Statistical analyses
Contingency tables with the maximum likelihood chi-square 
test as test statistic were used to compare nominal response 
variables with other nominal variables. Analysis of variance 
(ANOVA) was used to compare continuous response variables 
with nominal variables. Levene’s test was used to check for 
homogeneity of variances, and the Shapiro-Wilk test to test 
the residuals for normality. The Mann-Whitney U-test or the 
Kruskal-Wallis test was used if the residuals from the ANOVA 
were not normally distributed or if the response variable was 
ordinal. A significance level of 5% was used in all statistical 
tests.
Results
Demographic data and other outcomes in the entire sample, 
and those with a current depressive disorder, a current anxiety 
disorder, any depressive disorder (current or lifetime), any 
anxiety disorder (current or lifetime), and any co-morbid 
depressive/anxiety disorder (current or lifetime) are shown in 
Table I. The sample consisted of 5 males (9.8%) and 46 females 
(90.2%); mean age 39.6 years (standard deviation (SD) 9.9). 
The majority were Caucasian, married, employed, and had a 
secondary school education.
Dysthymic disorder (N=14 - 27.5%) was the most common 
current depressive disorder, followed by current major 
depressive disorder (MDD) (N=1 - 2%). Generalised anxiety 
disorder (N=24 - 47.1%) was the most common current anxiety 
disorder, followed by social anxiety disorder (N=10 - 19.6%), 
agoraphobia (N=3 - 5.9%) and panic disorder (N=2 - 3.9%). MDD 
(49%) was the most common lifetime depressive disorder, and 13 
(25.5%) patients met diagnostic criteria for a lifetime panic 
disorder. Any current co-morbid depressive disorder was 
present in 29.4% (N=15) of patients, and a current co-morbid 
anxiety disorder in 52.9% (N=27). Any anxiety disorder (current 
or lifetime) was reported in 60.8% (N=31), and any depressive 
disorder (current or lifetime) in 60.8% (N=31) of MSD patients. A 
current or lifetime co-morbid depressive or anxiety disorder 
was present in 74.5% (N=38) of participants. It was notable that 
most patients with lifetime co-morbid disorder also had a 
current co-morbid disorder, suggesting chronicity of the co-
morbidity.
Physical symptom count and disability measures were 
compared in those with/without a co-morbid depressive or 
anxiety disorder. Significantly higher physical symptom counts 
were reported by MSD participants with a current or lifetime 
depressive disorder (p=0.003), and by those with any current 
or lifetime co-morbid depressive or anxiety disorder (p=0.004). 
MSD patients with a current co-morbid depressive disorder 
had a significantly higher degree of overall (p=0.0476), social 
life (p=0.022) and family life/home responsibility (p=0.01) 
impairment than those without such co-morbidity.  Those with 
a current or lifetime depressive disorder reported significantly 
more overall impaired functioning (p=0.02) and impaired 
family life/home responsibilities (p<0.0005) than those without 
such a disorder. Those with any co-morbid depressive or 
anxiety disorder (current or lifetime) had significantly more 
family life/home responsibility impairment (p=0.003) than 
those without.
Mean PHQ-15 scores and disability measures of patients 
with any 1, 2, 3 and 4 or more co-morbid disorders were 
compared. A greater number of co-morbid disorders tended 
to be related to greater symptom severity, and 4 or more co-
morbid disorders were associated with significantly higher 
levels of overall disability (p=0.041) and impaired family life/
home responsibilities (p=0.0046).
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Age, gender, race, marital status, level of education, and 
VAS-P pain rating scores did not differ significantly between 
patients with or without a co-morbid disorder. However, 
employment status differed significantly across the groups. 
Compared to the entire sample (60.8% employed v. 39.2% 
unemployed), patients with a current or lifetime depressive 
disorder (48.4% employed v. 51.6% unemployed; p=0.021) 
and those with any current or lifetime co-morbid anxiety/
depression (52.6% employed v. 47.4% unemployed; p=0.032) 
had higher unemployment rates.
MSD patients with any co-morbid depressive or anxiety 
disorder (current or lifetime) had significantly more health 
care visits in the 3 months preceding evaluation (p=0.049). 
Participants with a co-morbid depressive disorder (current 
or lifetime) were rated as more difficult and frustrating by 
clinicians (p=0.02); and these patients rated their overall health 
care in the past 6 months as poorer (p=0.031) than those who 
had MSD only.
Discussion
The main findings of this study were: (i) a high prevalence 
of co-morbid depressive and anxiety disorders in South 
African subjects with MSD, consistent with previous reports 
in developed countries;3,9 (ii) significant associations of 
co-morbidity in MSD with somatic symptom count; and 
(iii) significant associations of co-morbidity in MSD with 
disability, clinician-experienced difficulties and lack of patient 
satisfaction.
Previous literature indicates that total somatic symptom 
count (irrespective of cause) is strongly predictive of the 
presence of a psychiatric disorder.3,5,8 In our MSD sample, 
a high somatic symptom count was associated with the 
likelihood of a co-morbid depressive or anxiety disorder.
MSD patients with any co-morbid depressive or anxiety 
disorder were significantly more disabled, and were more 
likely to be unemployed and make greater use of health 
care services than those with MSD only. Moreover, having 
Table I. Patient characteristics and outcomes (means are reported for continuous responses and percentages for nominal 
responses)
             Current or     Current or  Any 
      Entire            Current           Current    lifetime     lifetime  depression 
      sample            depression          anxiety    depression    anxiety  and/or anxiety
No. of patients     51 (100%)         15 (30%)          27 (52.9%)    31 (60%)    31 (60%) 38 (74.5%)
Female, N  (%)     46 (90.2%)        13 (86.7%)          25 (92.6%)    28 (90.3%)    29 (93.5%) 35 (92.1%)
Male, N  (%)     5 (9.8%)            2 (13.3%)          2 (7.4%)    3 (9.7%)     2 (6.5%)  3 (7.9%)
Mean age in years (±SD)    40 (10)            40.5 (8)          40 (10)    40 (9.5)     40 (10)  40.5 (9.5)
Employment 
Employed     31 (60.8%)        6 (40%)          14 (51.9%)    15 (48.4%)     16 (51.6%) 20 (52.6%) 
           *p=0.021   *p=0.032
   Unemployed     20 (39.2%)        9 (60%)          13 (48.1%)    16 (51.6%)     15 (48.4%) 18 (47.4%)  
           *p=0.021   *p=0.032
   Unemployed and     2 (3.9%)            2 (13.3%)          1 (3.7%)    2 (6.5%)     1 (3.2%)  2 (5.3%) 
   receiving a disability
   grant 
Sick days off work      3.63            2.20          2.82     4.92     2.62  4.06
in past 3 months
Health care visits      4.66            4.07          4.07     4.20      4.16  4.11 
in past 3 months           *p=0.049
PHQ-15 total     15.98            17.33          17.07    17.58      16.97  17.13 
           *p=0.003   *p=0.004
SDS total      17.02            20.20           18.44    18.9      17.81  18.13
               *p=0.0476      *p=0.02
SDS work     5.92            6.20          6.22     6.29     5.94  6.05
SDS social life     5.57            7.00           6.11     6.06     5.90  5.92
               *p=0.022
SDS family life/     5.53            7.00           6.11     6.55      5.97  6.16 
home responsibilities             *p=0.01      *p<0.0005   *p=0.003
VAS-P      6.24            6.53          6.59     6.61     6.29  6.45
DDPRQ-10     33.33            35.80          34.50    35.43      34.66  33.99
           *p=0.02
CAHPS overall quality     6.65            5.80          6.40     5.9      6.67  6.55
of health care past 6 months         *p=0.013
*p<0.05 in MSD patients with co-morbid disorders v. those without.
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≥4 co-morbid disorders was significantly associated with 
greater functional impairment and poorer family life/home 
responsibilities. The presence of a co-morbid depressive 
disorder was associated with increased clinician frustration 
and patient dissatisfaction with the overall quality of health 
care services. These findings are consistent with previous 
literature: somatisation has a detrimental effect on various 
health outcomes,5,7 and the presence of a co-morbid depressive 
disorder may have a cumulative effect on impairment, medical 
utilisation, clinician-experienced difficulties and patient 
dissatisfaction.
High rates of co-morbidity may lead to suggestions that 
somatoform disorders be better conceptualised as a severity 
marker of depression or anxiety, rather than an independent 
disorder. However, some evidence is consistent with the 
concept of MSD as an independent disorder. In our sample, 
a quarter of the patients had no co-morbid depressive or 
anxiety disorder. Previous literature indicates that medically 
unexplained symptoms often arise without concurrent 
depression or anxiety, with at least a third of such patients 
having somatisation alone.3,5,7,8 Moreover, MDD has an episode 
co-morbidity of 63 - 66%.16,17 These rates are not so different 
from co-morbidity rates reported in studies on somatoform 
disorders as to argue that MDD is an independent entity, 
whereas somatoform disorders are not.
Limitations of this study include a small sample size, 
predominantly female participants, and selection bias (MSD 
participants were recruited for a treatment study that excluded 
those with bipolar mood disorder, psychotic disorder, and 
present or recent substance use disorders). However, results 
from our study might not have been greatly affected by the 
selection process, as previous literature reported a relatively 
low incidence of these disorders in somatisation: mania (4.2% 
prevalence), followed by substance abuse (4.9% prevalence), 
were reported as less common co-morbidities in a sample with 
somatisation disorder.9,18
In conclusion, MSD with co-morbid depressive and anxiety 
disorders is common in primary care. Such co-morbidities are 
associated with an increased number of somatic symptoms, 
greater disability, increased provider frustration, and patients’ 
unmet health care expectations. However, delineating the 
relationship between somatisation and depressive and anxiety 
disorders still holds many challenges. Future research may 
address the pathophysiology and clinical course of MSD in 
those with/without co-morbidity, and investigate the influence 
of certain genetic and environmental factors (e.g. childhood 
adversities) on its pathogenesis.
At the time that this study was conducted, Professor Stein and Dr 
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